DA
EIKN icon

DCF Advisers’s Eikon Therapeutics EIKN Stock Holding History

DCF Advisers’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$272K Buy
+33,792
New +$340K 0.06% 97

Other funds holding EIKN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Regents of the University of California
Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

DCF Advisers's EIKN Position: Q3 2026 in Review

DCF Advisers opened a new position in Eikon Therapeutics (EIKN) in Q3 2026: 33,792 shares worth $272K. The stake represents 0.06% of the portfolio and ranks #97 among its holdings.

28 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

  • DCF Advisers held 33,792 shares of Eikon Therapeutics worth $272K as of Q3 2026.
  • Eikon Therapeutics was a new DCF Advisers position in Q3 2026.
  • Eikon Therapeutics made up 0.06% of DCF Advisers's portfolio in Q3 2026, its #97 holding.
  • 28 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on DCF Advisers's 13F filing for Q3 2026, filed 4 Nov 2026.